Thus, these results in 2 independent validation cohorts validate galectin‐9 and CXCL10 as strong biomarkers for disease activity in patients with juvenile DM, outperforming the currently used laboratory marker CK. The gene discussed is CXCL10; the disease is dermatomyositis.